Delivery Order SPE2DB24D2205-SPE2DB25FEFQB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens in 0.5 mL quantities, with a ceiling value of $7,625.80. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The order is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens. The contract, which is a child order under a larger vehicle, carries an ultimate completion date of August 14, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,306.78 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This competitive award, with a completion date of July 30, 2025, represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply arrangements with the federal government. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where the company operates as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Zepbound 5 mg/0.5 ml pens, with a contract value of $6,827.77 and completion deadline of August 22, 2025. This is a firm fixed-price, non-set-aside delivery order classified as a child contract, indicating it was issued under a larger indefinite delivery vehicle. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,233.41 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on July 31, 2025, with completion scheduled for August 1, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens in 0.5 mL quantities, with a contract ceiling value of $2,287.80 and an ultimate completion date of August 14, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a small-value transaction under AmerisourceBergen's larger pharmaceutical supply contract vehicle. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,138.12 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 31, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract calls for delivery to be completed by August 1, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $5,103.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injections on September 22, 2025, with completion scheduled for September 23, 2025. This award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside designation, and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injectors, valued at $10,709.65 with a firm fixed price structure. The order is scheduled for completion by July 24, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a non-set-aside competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEFQBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound 5 mg/0.5 mL pens in 0.5 mL quantities, with a ceiling value of $22,471.17. This firm fixed-price delivery order, with an ultimate completion date of July 31, 2025, represents a competitively awarded, non-set-aside contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing this work at its corporate office location in the same municipality. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract number SPE2DX), valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs. The award of this delivery order for Zepbound, a GLP-1 receptor agonist medication, demonstrates the contractor's ongoing role in providing specialty pharmaceuticals to federal healthcare systems, including the Defense Health Agency and other government medical programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.5k | 7/30/25 |